A blood ketone meter is used to test for blood levels of beta hydroxybutyrate, a ketone that the body produces when in ketosis, a natural metabolic state that involves the body producing ketone bodies out of fat and using them for energy instead of carbs. Blood ketone meters play a major role in treatment and management of diabetic ketoacidosis, a serious complication of type 1 diabetes and much less common in type 2 diabetes.
The blood ketone meter market is expected to witness significant growth with high incidence of diabetes worldwide. According to the study, “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition”, published in the journal Diabetes Research and Clinical Practice, in September 2019, 463 million people are expected to suffer from diabetes in 2019 worldwide and the number is expected to reach 578 million by 2030 and 700 million by 2045.
Such high prevalence of diabetes has increased the need for improving patient access to diabetes care diagnostics through the provision of affordable, easy-to-use technology, reducing the cost of long-term healthcare of the growing diabetic and pre-diabetic population. In line with the strategy and in order to enhance its share in the blood ketone meter market, in 2020, EKF Diagnostics, an in vitro diagnostics company, launched STAT-Site WB, a dual-use whole blood β-ketone and glucose meter for professional use in the management of diabetes.
People with diabetes can intervene early to address the underlying cause and help prevent dangerous progression of the disease with the proper information and early warning. Major players in the blood ketone meter market have considered this as a lucrative growth opportunity and invested in designing solutions that alert users of increasing ketone levels and continue to monitor these levels after intervention. One such company, PercuSense, in 2020, was awarded a US$ 2.5 million program-related investment for R&D in novel continuous monitoring system that measures both glucose and ketones on a single minimally invasive probe.
Emergence of Covid-19 has increased concerns over treatment and management of people suffering from obesity and diabetes. People suffering from such lifestyle disorders are at high risk of infection from the novel coronavirus. This has further offered lucrative growth opportunities for players in the market.
No comments:
Post a Comment